scholarly article | Q13442814 |
P2093 | author name string | Juan S Leon | |
David M Engman | |||
Kenneth V Hyland | |||
Melvin D Daniels | |||
Nick Giafis | |||
Kegiang Wang | |||
Thomas J Bahk | |||
LaKitta M Woods | |||
P2860 | cites work | Trypanosoma cruzi: antibodies to a MAP-like protein in chronic Chagas' disease cross-react with mammalian cytoskeleton | Q33481437 |
Chagas' disease and the autoimmunity hypothesis | Q33588893 | ||
Chagas disease etiology: autoimmunity or parasite persistence? | Q33632782 | ||
Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease | Q33722151 | ||
Aspects of cytotoxic T cell memory | Q41091852 | ||
Anti-CD4 abrogates rejection and reestablishes long-term tolerance to syngeneic newborn hearts grafted in mice chronically infected with Trypanosoma cruzi | Q41823109 | ||
Parasite persistence correlates with disease severity and localization in chronic Chagas' disease | Q42605133 | ||
T-cell molecular mimicry in Chagas disease: identification and partial structural analysis of multiple cross-reactive epitopes between Trypanosoma cruzi B13 and cardiac myosin heavy chain | Q42653469 | ||
Etiology of Chagas disease myocarditis: autoimmunity, parasite persistence, or both? | Q43890969 | ||
Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure | Q44116597 | ||
Use of a purified Trypanosoma cruzi antigen and CpG oligodeoxynucleotides for immunoprotection against a lethal challenge with trypomastigotes | Q44646613 | ||
Increased susceptibility of Stat4-deficient and enhanced resistance in Stat6-deficient mice to infection with Trypanosoma cruzi | Q44684713 | ||
Progress towards interruption of transmission of Chagas disease | Q44910717 | ||
Experimental chronic Chagas' disease myocarditis is an autoimmune disease preventable by induction of immunological tolerance to myocardial antigens | Q45169566 | ||
Antibodies to beta 1 and beta 2 adrenoreceptors in Chagas' disease | Q46161530 | ||
Humoral autoimmune response to ribosomal P proteins in chronic Chagas heart disease | Q47870383 | ||
Treatment of experimental chronic chagas disease with trifluralin | Q48707094 | ||
Interleukin-4 biases differentiation of B cells from Trypanosoma cruzi-infected mice and restrains their fratricide: role of Fas ligand down-regulation and MHC class II-transactivator up-regulation. | Q52008485 | ||
Trypanosoma cruzi: serum antibody reactivity to the parasite antigens in susceptible and resistant mice. | Q54321039 | ||
Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic chagas heart disease. | Q54727747 | ||
Changes in cell populations and immunoglobulin-producing cells in the spleens of mice infected with Trypanosoma cruzi: Correlations with parasite-specific antibody response | Q57203314 | ||
Chagas' disease | Q58844005 | ||
Cardiac antigen-specific autoantibody production is associated with cardiomyopathy in Trypanosoma cruzi-infected mice | Q58844027 | ||
Xid-associated resistance to experimental Chagas' disease is IFN-gamma dependent | Q58844145 | ||
Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease | Q58845107 | ||
Myosin autoimmunity is not essential for cardiac inflammation in acute Chagas' disease | Q58845899 | ||
Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease | Q58846997 | ||
In-vivo treatment with benznidazole enhances phagocytosis, parasite destruction and cytokine release by macrophages during infection with a drug-susceptible but not with a derived drug-resistant Trypansoma cruzi population | Q58847063 | ||
Secretion by Trypanosoma cruzi of a hemolysin active at low pH | Q69060121 | ||
Molecular mimicry and autoimmune disease | Q69205630 | ||
Chronic chagasic tissue lesions in the absence of Trypanosoma cruzi: a proposed mechanism | Q80381485 | ||
Cardiac parasympathetic abnormalities: Cause or consequence of chagas heart disease? | Q80818267 | ||
Cellular autoimmunity to cardiac myosin in patients with a recent myocardial infarction | Q81595089 | ||
Virus-specific and bystander CD8 T cells recruited during virus-induced encephalomyelitis | Q33724194 | ||
Cardiac myosin autoimmunity in acute Chagas' heart disease | Q34009000 | ||
Role of neurotransmitter autoantibodies in the pathogenesis of chagasic peripheral dysautonomia. | Q34196250 | ||
Parasite persistence in the aetiology of Chagas disease | Q34240113 | ||
Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection | Q34252265 | ||
Autoimmunity in Chagas disease cardiopathy: biological relevance of a cardiac myosin-specific epitope crossreactive to an immunodominant Trypanosoma cruzi antigen. | Q34453015 | ||
The pathogenesis of Chagas' disease: when autoimmune and parasite-specific immune responses meet. | Q34463172 | ||
Pathogenesis of Chagas heart disease: role of autoimmunity | Q34500622 | ||
Autoimmunity in Chagas' disease: specific inhibition of reactivity of CD4+ T cells against myosin in mice chronically infected with Trypanosoma cruzi. | Q35101438 | ||
The significance of autoimmunity in the pathogenesis of chagas heart disease | Q35109331 | ||
Autoimmunity and molecular mimicry in the pathogenesis of post streptococcal heart disease | Q35109368 | ||
Identification of major Trypanosoma cruzi antigenic determinants in chronic Chagas' heart disease | Q35162429 | ||
Molecular mimicry between Trypanosoma cruzi and host nervous tissues | Q35246043 | ||
Chagas disease: a role for autoimmunity? | Q35547443 | ||
Life-spans of human T-cell responses to determinants from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium vivax | Q35554701 | ||
Specific chemotherapy of Chagas disease: controversies and advances | Q35569069 | ||
Parasitic diseases of the heart | Q35650927 | ||
T cell mimicry in inflammatory heart disease | Q35704727 | ||
Autoimmunity in chagas disease cardiomyopathy: Fulfilling the criteria at last? | Q35846112 | ||
Longevity of the immune response and memory to blood-stage malaria infection. | Q36304674 | ||
Fl-160. A surface antigen of Trypanosoma cruzi that mimics mammalian nervous tissue | Q36356249 | ||
Mimicry in Trypanosoma cruzi: fantasy and reality | Q36845308 | ||
Do self-heart-reactive T cells expand in Trypanosoma cruzi-immune hosts? | Q37005726 | ||
Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses | Q37385100 | ||
Molecular mimicry by Trypanosoma cruzi: the F1-160 epitope that mimics mammalian nerve can be mapped to a 12-amino acid peptide | Q37545197 | ||
Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. | Q38957765 | ||
Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection | Q39218496 | ||
Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries | Q39262265 | ||
Antibodies to an epitope from the Cha human autoantigen are markers of Chagas' disease. | Q39508836 | ||
Trypanosoma Cruzi-Sensitized T-Lymphocyte Mediated 51Cr Release from Human Heart Cells in Chagas' Disease * | Q39522787 | ||
Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi | Q39559044 | ||
Autoimmunity in Chagas' disease. Identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas' cardiomyopathy patient | Q39772057 | ||
Free Radical Metabolites in the Mode of Action of Chemotherapeutic Agents and Phagocytic Cells on Trypanosoma cruzi | Q40142374 | ||
A cardiac myosin-specific autoimmune response is induced by immunization with Trypanosoma cruzi proteins | Q40882932 | ||
Benznidazole, a drug employed in the treatment of Chagas' disease, down-regulates the synthesis of nitrite and cytokines by murine stimulated macrophages | Q40919170 | ||
Molecular mimicry between cardiac myosin and Trypanosoma cruzi antigen B13: identification of a B13-driven human T cell clone that recognizes cardiac myosin. | Q41052780 | ||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | infectious disease | Q18123741 |
P304 | page(s) | 3641-3650 | |
P577 | publication date | 2007-05-07 | |
P1433 | published in | Infection and Immunity | Q6029193 |
P1476 | title | Modulation of autoimmunity by treatment of an infectious disease | |
P478 | volume | 75 |
Q37952062 | Advances and challenges towards a vaccine against Chagas disease. |
Q93184904 | Advances in nanocarriers as drug delivery systems in Chagas disease |
Q38412987 | Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead |
Q46613780 | Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. |
Q41760091 | Bioluminescent imaging of Trypanosoma cruzi infection |
Q44113294 | Cardiac damage induced by immunization with heat-killed Trypanosoma cruzi is not antibody mediated |
Q37264799 | Chagas heart disease pathogenesis: one mechanism or many? |
Q37310959 | Chagas' disease: an update on immune mechanisms and therapeutic strategies |
Q46567888 | Chemotherapy of chronic indeterminate Chagas disease: a novel approach to treatment |
Q36933422 | Curcumin Enhances the Anti-Trypanosoma cruzi Activity of Benznidazole-Based Chemotherapy in Acute Experimental Chagas Disease |
Q37151780 | Current concepts in immunoregulation and pathology of human Chagas disease |
Q43623255 | DNA repair BER pathway inhibition increases cell death caused by oxidative DNA damage in Trypanosoma cruzi. |
Q41552272 | Depletion of regulatory T cells decreases cardiac parasitosis and inflammation in experimental Chagas disease |
Q39836484 | Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells |
Q27301348 | Endothelial transmigration by Trypanosoma cruzi |
Q36901969 | Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine |
Q33809208 | Heat-killed Trypanosoma cruzi induces acute cardiac damage and polyantigenic autoimmunity |
Q37272449 | Host and parasite genetics shape a link between Trypanosoma cruzi infection dynamics and chronic cardiomyopathy |
Q34707808 | Humoral immune response against P2β from Trypanosoma cruzi in persons with chronic Chagas disease: its relationship with treatment against parasites and myocardial damage |
Q92765270 | Low-Level Parasite Persistence Drives Vasculitis and Myositis in Skeletal Muscle of Mice Chronically Infected with Trypanosoma cruzi |
Q26858780 | Mechanisms of Trypanosoma cruzi persistence in Chagas disease |
Q42554282 | Monocyte activation by necrotic cells is promoted by mitochondrial proteins and formyl peptide receptors |
Q33587960 | New perspectives of infections in cardiovascular disease |
Q37625574 | Parasitic infection and autoimmunity |
Q40291208 | Pathogenesis of Chagas disease: time to move on. |
Q28742827 | Pathogenesis of chagas' disease: parasite persistence and autoimmunity |
Q57789637 | Pathology and Pathogenesis of Chagas Heart Disease |
Q95841203 | Precision Health for Chagas Disease: Integrating Parasite and Host Factors to Predict Outcome of Infection and Response to Therapy |
Q38950397 | Putting Infection Dynamics at the Heart of Chagas Disease |
Q38256874 | Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives |
Q37544885 | Towards a paradigm shift in the treatment of chronic Chagas disease. |
Search more.